allogeneic CD3- CD19- CD57+ NKG2C+ NK cells FATE-NK100

{
  "id": "MLC-T-ONC-009851",
  "term": "allogeneic CD3- CD19- CD57+ NKG2C+ NK cells FATE-NK100",
  "field": "Oncology and biomedicine",
  "definition": "A preparation of pharmacologically-enriched, allogeneic natural killer (NK) cells derived from a related, but not completely matched, human leukocyte antigen (HLA)-haploidentical donor that is seropositive for cytomegalovirus (CMV+), with potential cytolytic and antineoplastic activities. Upon leukapheresis, the donor peripheral blood mononuclear cells (PBMCs) are treated to remove T lymphocytes (CD3+) and B lymphocytes (CD19+). The remaining leukocytes are cultured for 7 days with the cytokine interleukin-15 (IL-15) and a small molecule inhibitor of glycogen synthase kinase 3-beta (GSK3beta) to generate the adaptive, CD3- CD19- CD57+ NKG2C+ NK cells FATE-NK100 ex vivo. Upon infusion of the allogeneic CD3- CD19- CD57+ NKG2C+ NK cells FATE-NK100, these cells selectively recognize and bind to tumor cells, and secrete perforins, granzymes, and cytokines, which results in cancer cell lysis. Exposure to CMV induces the expression of the memory-like activating receptor NKG2C and the maturation marker CD57 in the isolated NK cells, making them more potent than those not pre-exposed to CMV. CD57 both enhances the effector function of NK cells and stimulates CD16-dependent signaling. Treatment with IL-15 enhances NK cell proliferation and survival. The GSK3beta inhibitor induces preferential expansion of CD57+ NK cells that exhibit enhanced interferon (IFN)-gamma production.",
  "synonyms": [
    "adaptive memory NK cells FATE-NK100",
    "adaptive NKs cells FATE-NK100",
    "adaptive memory natural killer cells FATE-NK100"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/allogeneic-cd3-cd19-cd57-plus-nkg2c-plus-nk-cells-fate-nk100/"
}